Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Video content above is prompted by the following:
Do you have any clinical pearls for the community oncologist?